LifeVantage Corporation (LFVN)
LifeVantage Corporation (LFVN) Stock Price, Analysis & Data
| Bid | 4.72 |
| Market Cap | 82.13M |
| Revenue (ttm) | 195.32M |
| Net Income (ttm) | 5.75M |
| Beta | 0.76 |
| EPS (ttm) | 0.44 |
| PE Ratio (ttm) | 14.8 |
| Forward PE | 14.26 |
| P/B (ttm) | 2.46 |
| P/S (ttm) | 0.42 |
| Earnings Date | Sep 3, 2026 |
| Ask | 8.33 |
| Volume | 81,836 |
| Avg. Volume (20D) | 414,158 |
| Open | 6.69 |
| Previous Close | 6.66 |
| Day's Range | 6.32 - 6.69 |
| 52-Week Range | 3.90 - 14.41 |
| Analyst | n/a |
| Price Target | 7 (7.53%) |
| Dividends | $0.2 (3%) |
| Ex-Dividend Date | Jun 1, 2026 |
About LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary sup...
Financial Performance
In 2025, LifeVantage's revenue was 228.53M, an increase of 14.17% compared to the previous year's 200.16M. Earnings were 9.8M, an increase of 233.84%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for LFVN stock is "null". The 12-month stock price forecast is 7, which is upside of 7.53% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
